Akiva Diamond

Malignant Hematologist @BCMCancerCenter focusing on lymphoma patients and research. Views are my own.

[Akiva Diamond @AkivaDiamond]

@VincentRK @mvmateos @ASH_hematology Really impressive! Honest question- what should be done with all the ongoing (or just opening) trials using Dpd/Dvd as a control arm? Would you still randomize?

[VJHemOnc @VJHemOnc]

It was wonderful to speak with @AkivaDiamond at #ASCO25 today! He shared insights into the use of multi-virus-specific T-cells to enhance the activity of bispecific antibodies in lymphoma.

Catch the full interview soon on https://t.co/Vqyt4afDXd 📹

@ASCO #LYMsm #ImmunoOnc #HemOnc

[Akiva Diamond @AkivaDiamond]

@RShouval Really interesting and very cool study! I would love to see if this inflammation signature is applicable to other treatment settings (I.e. BsAb)

[Akiva Diamond @AkivaDiamond]

@RShouval It’s possible that inflamed may be prognostic but not predictive. Perhaps it’s a epiphenomenon- more aggressive tumor biology increasing inflammation. prognostic value of becoming non-inflamed at infusion may reflect chemo sensitivity. I doubt window Toci/Anakinra would help

[Akiva Diamond @AkivaDiamond]

@graham74GC @vit_prochazka The data hasn’t really changed and the press release implies that the main change was they negotiated a better price with Takeda. Am I being too cynical to think they were willing to give a better price since most US based centers shifted to Nivo?

[Akiva Diamond @AkivaDiamond]

@majorajay Did they discuss why OS is > PFS? 2nd line r-mini-CHOP?

[Akiva Diamond @AkivaDiamond]

@Eddie_Cliff @BroeckelmannPJ The PFS overall is disappointing given median lines of prior therapy was 1, but happy to see the difference between their patients and those treated on augment. The R2 PFS looked similar to the R monotherapy arm of augment.

[Akiva Diamond @AkivaDiamond]

@graham74GC My takeaway was more the lack of benefit over BR. “For the subgroup with selection BR, the HR = 1.00 (0.70, 1.44), 5 year OS probability 57.2% vs 58.1%, for IR and BR, respectively.”

[Ang Li, MD, MS @AngLi_MD]

Baylor College of Medicine is seeking a full-time classical hematologist to join our clinical and research programs. We are located in the heart of Houston (not Waco): https://t.co/vvHJFjkri2

[Akiva Diamond @AkivaDiamond]

@RahulBanerjeeMD @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK Really interested to see what percent actual use twice weekly in routine clinical care

[Akiva Diamond @AkivaDiamond]

@RahulBanerjeeMD @GKaurMD @BoWangMD1 @ldandersonjr @VincentRK Looking forward to seeing the results.

[Akiva Diamond @AkivaDiamond]

Data is finally out!

median follow-up of 12.1 months, PFS was superior in the N-AVD arm [HR 0.48, 99% CI 0.27-0.87)

1y PFS:
N-AVD: 94%
BV-AVD: 86%

[Jonathan Friedberg @DrJFriedberg]

Today is the day! @SWOG 1826 data will be presented at @ASCO plenary, with discussion from @DrLaCasce

https://t.co/ZnA7gu64iW

[Akiva Diamond @AkivaDiamond]

It’s interesting to note that ibrutinib approval seems to be associated with decreased BR use but chlorambucil rates remained low and steady.

[Akiva Diamond @AkivaDiamond]

Excited to share our paper published in @LeukemiaJnl “Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials” https://t.co/o5ZHZh0oxe

We were interested to look at treatment patterns during the era of the early ibrutinib trials 🧵 1/n

[Akiva Diamond @AkivaDiamond]

Our data show that in the period when chlorambucil was used as a control arm in ibrutinib trials, CLL patients of comparable age were more commonly treated with more aggressive therapies